Multaq Tablet, Film Coated
Product Images NDC 0024-4142

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Multaq (NDC 0024-4142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Multaq 01)

FDA Label Image

Figure 1 (Multaq 02)

Figure 1 (Multaq 02)
This text appears to be displaying a list of interacting drugs and their corresponding recommendations for use together. Some drugs are contraindicated while others require no dose adjustments. There is mention of antibiotics such as ketoconazole, erythromycin, and rifampin, as well as calcium channel blockers like diltiazem, verapamil, and nifedigine. Statins like simvastatin and atorvastatin are also mentioned. Additionally, there is a warning to avoid concomitant use with grapefruit juice. However, the last line of text is not readable.*
FDA Label Image

Figure 2 (Multaq 03)

Figure 2 (Multaq 03)
This is a list of medications and their recommended interactions. The medication names include statins, digitalis, beta blockers, calcium channel blockers, antithrombotic agents, Losartan, Metformin, Ethinyl estradiol, Levonorgestrel, Omeprazole, and Theophylline. The information includes recommended dose adjustments for certain drugs when taken together and/or monitoring of certain parameters. There are also some measurements shown for Cmax and AUC.*
FDA Label Image

Figure 3 (Multaq 04)

FDA Label Image

Figure 2 (Multaq 05)

Figure 2 (Multaq 05)
Characteristic N RR [95%CT] for different parameters such as age, Structural Heart Disease, NYHA class, LVEF(%), EBeta blocking agents, ACE inhibitors or ARBs are given. The values for some parameters are not available. The comparison of DronedaroneBetter and Placebo Better is also provided.*
FDA Label Image

Principal Display Panel (60 Tablet Bottle)

Principal Display Panel (60 Tablet Bottle)
This is a medication package containing 60 tablets of 400mg each. The brand name of the medication is "Multag" which is produced by Sanofi. However, the information is not complete and therefore insufficient to provide further details.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.